New research has added to the growing body of evidence linking Actos to increased adverse health risks including bladder cancer, pancreatic cancer and prostate cancer.
Free Confidential Case Evaluation: If you or a loved one has suffered from bladder cancer, macular edema, heart problems or other serious side effects after taking Actos, you should contact our law firm immediately. You may be entitled to compensation by filing a lawsuit and our lawyers can help.
Update: FDA Confirms Actos Bladder Cancer Link
December 15, 2016 – FDA has updated its review of Actos, confirming that use of the drug may increase the risk of bladder cancer. While Actos labels already contain a warning about the bladder cancer risk, the agency is once again updating the labeling to describe the additional studies it has reviewed.
Actos (pioglitazone hydrochloride) Side Effects
Actos is an oral medication which is used for treatment of Type 2 diabetes. It is part of the same class of drugs as Avandia (rosiglitazone), which has been the focus of concern in the medical community since reports found that Avandia may increase the risk of heart attacks and heart related death.
Actos side effects include (but are not limited to):
- congestive heart failure (CHF)
- heart attack
- liver problems
- bladder cancer
- macular edema
The link between Actos and heart failure is strong enough that in 2007 the FDA increased the warnings on the drug concerning congestive heart failure.
Actos and Bladder Cancer
In June 2011, the U.S. Food & Drug Administration (FDA) issued a warning concerning Actos and bladder cancer. The warning was prompted by a review of data from a five-year analysis of an ongoing study conducted by Takeda Pharmaceuticals, the company that makes Actos. While there was no overall increased risk of bladder cancer among patients treated with the drug, individuals with the longest exposure to pioglitazone had a greater chance of developing the disease. Specifically, the study indicated that patients who used Actos for more than 12 months had a 40% higher risk of developing bladder cancer.
In light of this information, the FDA has recommended that Actos be avoided in patients with pre-existing bladder cancer, as well as in those with a family history of the disease. The administration also advised users to be on alert for signs which may possibly indicate Actos bladder cancer, such as:
- Blood in urine
- Back or lower abdominal pain
- Urgent need to urinate
- Pain during urination
$2.37 Billion Actos Settlement Finalized
September 15, 2015 – Takeda now has 96% of claimants on board with its offer to settle thousands of Actos bladder cancer lawsuits for $2.37 billion, according to FiercePharma. With the settlement, Japan’s largest drugmaker hopes to turn the corner on its legal troubles and once again make the company profitable. Click here to learn more.
Actos Linked to 40% Increased Risk of Pancreatic Cancer: Study
July 21, 2015 – A study published today in the Journal of the American Medical Association (JAMA) that looked at data on more than 236,000 diabetes patients found that Actos use was associated with a 40% increased risk of pancreatic cancer, a disease that kills more than 40,000 Americans each year. The researchers cautioned that additional studies are needed to investigate the matter, and that it’s difficult to conclude from this study that Actos helps cause pancreatic cancer. Click here to learn more.
Actos and Prostate Cancer
The JAMA study cited above also found a link between Actos use and a 13% increased risk of prostate cancer, a serious disease that affects hundreds of thousands of American men each year. While the FDA has yet to warn consumers about the prostate / pancreatic cancer risk associated with Actos, the researchers believe their conclusions were convincing enough to warrant further studies.
“The increased prostate and pancreatic cancer risks associated with ever use of pioglitazone merit further investigation to assess whether they are causal or are due to chance, residual confounding, or reverse causality,” the researchers concluded. Click here to learn more.
Actos Settlement on Shaky Ground as Deadline Nears
Takeda’s $2.37 billion settlement of thousands of Actos bladder cancer lawsuits didn’t attract enough participants by the August 12, 2015 deadline to move forward, raising doubts about whether the deal will survive. The drugmaker is obligated to fund the settlement after 95% of plaintiffs join it; however, by August 12 only about 75% had agreed to the deal, so the deadline was pushed back to September 11. Click here to learn more.
Additional Resources & Information
- Actos Bladder Cancer Lawsuit Filed by Blue Cross
- Judge Warns Takeda Over Bad Behavior in Actos Bladder Cancer Litigation
- Jury Awards $9 Billion in Actos Bladder Cancer Lawsuit
Do I have an Actos Lawsuit?
The Defective Drug & Product Liability Litigation Group at our law firm is an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in Actos side effects lawsuits. We are handling individual litigation nationwide and currently accepting new cases in all 50 states.
If you or a loved one has suffered from bladder cancer, macular edema, heart problems or other serious side effects after taking Actos, you should contact our law firm immediately. You may be entitled to compensation by filing a lawsuit and our lawyers can help.